Navigation Links
Genomatix technology facilitates de novo identification of new renal disease associated genes

Previously unknown molecules and regulatory pathways in human glomerular diseases have been identified by a joint effort of the Medizinische Poliklinik, Munich, the University of Bristol´s Children´s Renal Unit, the German Cancer Research Center, sanofi-aventis, and Genomatix Software GmbH.

In a joint publication in the Proceedings of the National Academy of Sciences of the United States of America (PNAS) above groups show how new bioinformatics approaches allow rapid characterization of shared promoter structures which can be used to find novel interacting molecules. Here, these principles are applied to a set of genes linked to the unique functional unit of the glomerular slit diaphragm. An evolutionarily conserved promoter model was generated. Genome-wide scans using this promoter model effectively predicted a previously unrecognized slit diaphragm molecule which was then experimentally verified.

This publication shows a straightforward approach how comparative promoter analysis can identify regulatory pathways at work in tissue homeostasis and disease processes.


'"/>

Source:Genomatix Software GmbH


Page: 1

Related biology news :

1. Genomatix, AAAS ink agreement
2. Genomatix Microarray Analysis Pipeline achieves Affymetrix GeneChip compatible?status
3. MatBase -- A new transcription factor knowledge base released by Genomatix
4. Application of Genomatix in silico methods reveals novel cancer associated genes
5. Novel technology detects human DNA mutations
6. Novel antiviral technology inhibits RSV infection in mice
7. The BIOS Initiative - open source biotechnology is born
8. Revolutionary nanotechnology illuminates brain cells at work
9. Study: homemade gene expression technology unreliable
10. First technology to remove prions that cause vCJD from blood launched
11. Integration of Agilents MS technology, Proteome Systems software to help scientists in proteomics research
Post Your Comments:
(Date:4/17/2014)... 2014The development of stem cell therapies to cure a ... stem cell populations based on cell surface markers. Researchers ... marker that is highly expressed in a type of ... they describe in an article in BioResearch Open ... Inc., publishers. The article is available free on the ...
(Date:4/17/2014)... cartridge developed at Sandia National Laboratories and recently licensed ... and cheaper. , Bacillus anthracis , the ... all over the world and can cause serious, and ... bacteria can survive in harsh conditions for decades. In ... through skin contact, inhalation of spores or eating contaminated ...
(Date:4/17/2014)... to produce hydrogen sulfide in order to properly multiply ... from the Center for Craniofacial Molecular Biology at the ... Songtao Shi, principal investigator on the project, said the ... the flow of calcium ions. The essential ions activate ... or the creation of new bone tissue, and keeps ...
Breaking Biology News(10 mins):Pocket-sized anthrax detector aids global agriculture 2Pocket-sized anthrax detector aids global agriculture 3
... 9, 2009 A nutritionist whose research was instrumental in ... Children (WIC) food subsidy will receive the March of Dimes ... maternal-fetal nutrition. Gail Harrison, Ph.D., MNS, , ... the University of California, Los Angeles School of Public Health, ...
... 150th anniversary this month of the publication of On ... Sciences (AIBS) is publishing open access two peer-reviewed articles ... , The two articles are by Kevin Padian of ... of Western Carolina University. Padian,s article, "Ten Myths About ...
... Conn.Researchers at Yale University have developed synthetic molecules capable ... HIV-infected cells, as well as to prostate cancer cells. ... the American Chemical Society , could lead to novel ... called "antibody-recruiting molecule targeting HIV" (ARM-H) and "antibody-recruiting ...
Cached Biology News:March of Dimes honors Dr. Gail Harrison for outstanding work in maternal-fetal nutrition 2New synthetic molecules trigger immune response to HIV and prostate cancer 2
(Date:1/14/2014)... As pet owners drew up their lists of New Year,s ... better care of my furry companion." Nowadays there are pet salons, ... cases to take the little canine or feline darlings along wherever ... buy some pricey toys at the pet store. But anyone who ...
(Date:1/14/2014)... DIEGO and BETHESDA, Md. ... are joining together with two institutes from the National ... reliable tools for bringing safer, more effective treatments to ... the National Center for Advancing Translational Sciences (NCATS) and ...
(Date:1/14/2014)... 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology ... therapies addressing major unmet medical needs using RNA-targeted ... of Allowance from the United States Patent and ... (sd-rxRNA®), for the treatment of fibrosis. The patent ...
(Date:1/14/2014)... USA, and Cardiff, UK (PRWEB) January 13, 2014 ... technology development leader with more than 20 years in ... for optics and photonics . Hainsey will serve as ... delighted to have Dr. Hainsey join SPIE as our ...
Breaking Biology Technology:New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2
... MAISONS-ALFORT, France, April 14 /PRNewswire-FirstCall/,-- Cephalon, Inc. (Nasdaq: ... has granted marketing authorization for EFFENTORA(TM), a buccal,tablet ... treatment of,breakthrough cancer pain (BTCP) in adult patients ... pain. The approval allows Cephalon,to market EFFENTORA in ...
... blood-based ColonSentry(TM) test -, TORONTO, April 14 ... on developing blood-based biomarker tests for the early,detection ... performance results from a large validation study of ... patient,s current risk for,colorectal cancer. This panel forms ...
... ImaRx Therapeutics,Inc. (Nasdaq: IMRX ) today announced ... 11, 2008 indicating that for the last 30,consecutive business ... closed,below $1.00 per share. As a result, the company ... continued listing set forth in,Marketplace Rule 4310(c)(4)., In ...
Cached Biology Technology:Cephalon Announces European Commission Approval of EFFENTORA for the Treatment of Breakthrough Cancer Pain 2Cephalon Announces European Commission Approval of EFFENTORA for the Treatment of Breakthrough Cancer Pain 3Cephalon Announces European Commission Approval of EFFENTORA for the Treatment of Breakthrough Cancer Pain 4GeneNews reports positive results from validation study of colorectal cancer biomarkers in late-breaking abstract at AACR 2GeneNews reports positive results from validation study of colorectal cancer biomarkers in late-breaking abstract at AACR 3ImaRx Therapeutics Receives Notification from NASDAQ Regarding Non-Compliance with NASDAQ's Minimum Bid Price Requirement 2
... Science, which pioneered the blending of thermostable ... and Expand Long Template PCR Systems, now ... the first product of a family ... blend combines Taq DNA Polymerase with a ...
The HEPTEST assays provide a sensitive, simple, rapid, and convenient in vitro quantitation of heparin, low molecular weight heparins, and heparinoids in plasma and whole blood. Sample Type: wh...
...
... enzyme mix (Thermoprime Plus DNA Polymerase with ... four times higher fidelity than standard Taq ... Taq DNA polymerase, Amplifies DNA templates >20kb, ... PCR, PCR for cloning and mutagenesis We ...
Biology Products: